Mixed connective tissue disease secondary prevention

Mixed connective tissue disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mixed connective tissue disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mixed connective tissue disease secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mixed connective tissue disease secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
National Guidelines Clearinghouse
NICE Guidance
FDA on Mixed connective tissue disease secondary prevention
on Mixed connective tissue disease secondary prevention
Mixed connective tissue disease secondary prevention in the news
Blogs onMixed connective tissue disease secondary prevention
Directions to Hospitals Treating Mixed connective tissue disease
Risk calculators and risk factors for Mixed connective tissue disease secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Overview

In MCTD effective measures for the secondary prevention of Raynaud's disease include vasodilator therapies (such as calcium channel blockers), preventive approaches like avoidance of cold temperatures, smoking, and sympathomimetic agents and use of warm and protection techniques of fingers. Current strategies include Bosentan (endothelin receptor antagonist) as the recommended medication for the prevention of new digital ulcers.

Secondary Prevention

• In MCTD effective measures for the secondary prevention of Raynaud's disease include:
  • Vasodilator therapies (such as calcium channel blockers)
  • Preventive approaches like avoidance of cold temperatures, smoking, and sympathomimetic agents
  • Use of warm and protection techniques of fingers
• Current strategies include Bosentan (endothelin receptor antagonist) as the recommended medication for the prevention of new digital ulcers.